Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
Tags :dx2
DSM and Firmenich have successfully concluded their merger announced on 31 May 2022, becoming a powerful creation and innovation partner in nutrition, beauty, and well-being. The EUR 35 billion business combination solidifies their position in the industry.
GOLDBEK Holding, a fast growing and innovative German greeting card publishing company, has acquired 100% of ABC Kunst- und Glückwunschkartenverlag (its legal name is A. Boss & Co), a privately owned Swiss market leader in
Kellerhals Carrard has reorganised and strengthened its Life Sciences team. It is now fully integrated into the value chain of its clients in the pharmaceutical, medical technology, health and nutrition sectors and is led by
MLLStart! has advised automated retail technology company Invenda Group in its Series B Financing Round where additional USD 19 million have been raised. The financing round was led by Point Break Capital Management and existing investor
MLL Legal has signed an agreement with Swiss-based Logol Group for the implementation of their ELLE legal software. “Focus on being a lawyer, let ELLE do the rest” is not only how the ELLE legal
Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key
On 27 October 2022, with around 80 attendees, has took `place the first day of the Special Inhousecommunity Days. This edition of the event, which brings together leading lawyers, general counsel and in-house lawyers from renowned Swiss companies
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m. NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
On September 23, 2022, Roche Kapitalmarkt issued CHF 800 million Bonds guaranteed by Roche Holding. Credit Suisse and UBS acted as lead managers. The bonds will be listed on the SIX Swiss Exchange. The transaction consists of a
